Location History:
- Basel, CH (2011)
- Binen, DE (2019)
Company Filing History:
Years Active: 2011-2019
Title: Lorenz Mayr: Innovator in Therapeutic Antibodies and Proliferative Disease Treatments
Introduction
Lorenz Mayr is a distinguished inventor based in Munich, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies and compounds for treating proliferative diseases. With a total of two patents to his name, Mayr's work is recognized for its potential impact on medical treatments.
Latest Patents
Mayr's latest patents include innovative approaches to addressing critical health issues. The first patent, titled "Factor XI antibodies and methods of use," focuses on monoclonal antibodies that bind to human Factor XI and activated Factor XI (Factor XIa). This invention encompasses pharmaceutical compositions and treatment methods that leverage these antibodies for therapeutic purposes. The second patent, "3-imidazolyl-indoles for the treatment of proliferative diseases," describes compounds capable of inhibiting the interaction between p53 and MDM2/MDM4 variants. These compounds are promising for treating various disorders mediated by MDM2 and MDM4 activity, including inflammatory and proliferative diseases.
Career Highlights
Lorenz Mayr is currently associated with Novartis AG, a leading global healthcare company. His work at Novartis has allowed him to further his research and development efforts in the field of therapeutic innovations. Mayr's expertise and dedication to advancing medical science have positioned him as a